Researchers at the University of Kentucky have discovered that an investigational drug, originally developed for Alzheimer’s disease, may also help ease the symptoms of alcohol withdrawal. The drug, known as MW150, targets a specific brain inflammation pathway called p38α MAPK, which is associated with addiction and relapse.
Potential Breakthrough in Alcohol Use Disorder Treatment
The study, conducted by the Sanders-Brown Center on Aging, was led by neuroinflammation researcher Linda Van Eldik. It suggests that MW150 could mitigate the neuroinflammation that contributes to relapse risk and long-term neurological damage in individuals with alcohol use disorder. The findings were published in the journal Alcohol.
Caleb Bailey, PhD, a co-author of the study, emphasized the significance of these findings. He noted that if further experiments confirm MW150’s anti-inflammatory effects in animal models of alcohol use disorder, it could pave the way for developing the drug as a treatment for chronic alcohol relapse due to withdrawal.
Challenges and Future Directions
While the research shows promise, it is important to note that the experiments were conducted in cell cultures and animal models. Bailey highlighted the need for follow-up studies in living animals to fully understand the drug’s effects on systemic health and alcohol consumption.
MW150, along with a related compound called Neflamapimod, is already being tested in clinical trials for dementia and other neurodegenerative conditions. This existing research could expedite the repurposing of these drugs for alcohol-related conditions if future studies continue to show positive results.
Expert Opinions
Dr. Amy Swift, deputy chief medical officer at Silver Hill Hospital in Connecticut, who was not involved in the study, shared her insights on the findings. She pointed out that while detoxification is an essential first step in treating alcohol use disorder, it does not address the disorder itself. Adding medications that improve brain health could fill a critical gap in early treatment.
Bailey also stressed that no amount of alcohol consumption is beneficial for physical health, and minimizing alcohol intake remains the best strategy for maintaining health. As MW150 continues to be studied for dementia patients, understanding its interaction with alcohol will be crucial for patient outcomes.
Original reporting: Fox News (HLL/CB) — read the source article.
